Cambridge, MA, Reader Meetup Today (10/18) at 4:30p ET

In the Cambridge/Boston area this evening? Join well-connected FierceBiotech readers like yourself for a drink at Bambara Restaurant in Cambridge (map) at 4:30-7:00p ET. No RSVP is required, but feel free to give us a heads up by email or Twitter and we'll look out for you tonight.

We're in town for FierceBiotech's executive breakfast panel Wednesday morning, featuring Peter Mueller (Vertex Pharmaceuticals), Doug Williams (Biogen Idec), Tom Hughes (Zafgen), Omid Farokhzad (Harvard Medical School) and Stephen Knight (Fidelity Biosciences). John Carroll, our esteemed editor-in-chief, will moderate the discussion.

Thanks for being part of the Fierce community. If you're local, hope to see you either this evening or tomorrow.

- Arsalan Arif, Publisher (email | Twitter)

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.